Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma. Issue 11 (7th October 2015)

• Record Type: Journal Article
• Authors: Okamoto, Akinao; Yanada, Masamitsu; Miura, Hiroki; Inaguma, Yoko; Tokuda, Masutaka; Morishima, Satoko; Kanie, Tadaharu; Yamamoto, Yukiya; Mizuta, Shuichi; Akatsuka, Yoshiki; Yoshikawa, Tetsushi; Mizoguchi, Yoshikazu; Nakamura, Shigeo; Okamoto, Masataka; Emi, Nobuhiko
• Is Part Of: Cancer science. Volume 106:Issue 11(2015:Nov.)
• Page Start: 1576
• Page End: 1581
• Publication Date: 2015-10-07
• Subjects: Diffuse large B‐cell lymphoma -- EBER -- EBV DNA load -- Epstein–Barr virus (EBV); Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.12812
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract : It is still a matter of debate whether detection of Epstein–Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B‐cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B‐cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline‐based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94%). Epstein–Barr virus DNA was detected in 15 patients (12%), who were older ( P = 0.005) and tended to be at a more advanced disease stage ( P = 0.053). They showed significantly worse progression‐free survival (PFS) and overall survival (OS) than other patients ( P < 0.001 each). This effect remained significant ( P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV‐encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75%) and 9 of 115 negative patients (8%) had detectable EBV DNA in pretreatment serum. While patients positive for EBV‐encoded small RNA had significantly worse PFS and OS than negative patients ( P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV‐encoded small RNA ( P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B‐cell lymphoma. Abstract : For this study, we measured Epstein–Barr virus DNA load in pretreatment serum from 127 diffuse large B‐cell lymphoma patients to evaluate its effects on clinical manifestations and prognosis. Our findings show that Epstein–Barr virus DNA detection in pretreatment serum may have an adverse prognostic impact.